Eaton M P, Deeb G M
Department of Biostatistics, University of Rochester School of Medicine, NY 14642, USA.
J Cardiothorac Vasc Anesth. 1998 Oct;12(5):548-52. doi: 10.1016/s1053-0770(98)90099-4.
To compare the relative efficacy of aprotinin and epsilon-aminocaproic acid (EACA) in decreasing blood loss and transfusion requirements after aortic surgery involving deep hypothermic circulatory arrest (DHCA).
A retrospective chart review.
A university medical center.
Forty-nine patients who had undergone thoracic aortic surgery with the use of circulatory arrest.
Charts were examined for variables believed to influence postoperative blood loss, including the use of medications, and for the amount of postoperative chest tube drainage and perioperative transfusion.
Median chest tube output (CTO) at 6 and 12 hours postoperatively was nearly identical in patients treated with aprotinin or EACA (660 and 1,015 v 700 and 950 mL for aprotinin and EACA at 6 and 12 hours, respectively), as were total perioperative blood transfusions. Complications were not significantly different between groups with the exception of a trend toward increased incidence of renal failure in the group receiving EACA.
Aprotinin and EACA appear to be equally efficacious in reducing perioperative blood loss and transfusion requirements in patients undergoing aortic surgery involving DHCA. Questions of safety remain about the use of EACA in this setting that could not be addressed by this small retrospective study. A prospective, placebo-controlled study is warranted to confirm the absolute efficacy of these agents and to better define safety issues.
比较抑肽酶和ε-氨基己酸(EACA)在减少涉及深低温停循环(DHCA)的主动脉手术后失血及输血需求方面的相对疗效。
回顾性图表审查。
一所大学医学中心。
49例接受了使用体外循环的胸主动脉手术的患者。
检查图表中被认为会影响术后失血的变量,包括药物使用情况,以及术后胸腔引流管引流量和围手术期输血量。
接受抑肽酶或EACA治疗的患者术后6小时和12小时的胸腔引流管引流量中位数几乎相同(抑肽酶组在6小时和12小时分别为660和1015 mL,EACA组为700和950 mL),围手术期总输血量也相同。除了接受EACA的组中肾功能衰竭发生率有增加趋势外,两组并发症无显著差异。
在接受涉及DHCA的主动脉手术的患者中,抑肽酶和EACA在减少围手术期失血和输血需求方面似乎同样有效。在这种情况下使用EACA的安全性问题无法通过这项小型回顾性研究得到解决。有必要进行一项前瞻性、安慰剂对照研究,以确认这些药物的绝对疗效并更好地界定安全性问题。